A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan

Condition:   Attention Deficit Disorder With Hyperactivity Interventions:   Drug: MPH (Concerta);   Drug: MPH (Ritalin);   Drug: Atomoxetine (ATO);   Drug: Guanfacine (GFC) Sponsor:   Janssen Research & Development, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials